We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EBS market cap is 262.06M. The company's latest EPS is USD -14.5680 and P/E is -0.34.
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 330.7M | 165.1M | 337.9M | 269.7M | 276.6M |
| Operating Income | -65.1M | -148.1M | 13.8M | -548.3M | -73.7M |
| Net Income | -88M | -183M | -261.3M | -266.7M | -49.5M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.11B | 1.56B | 1.79B | 1.12B | 1.05B |
| Operating Income | 114.1M | 433.8M | 352.6M | -172.7M | -726.4M |
| Net Income | 54.5M | 305.1M | 230.9M | -223.8M | -760.5M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.17B | 2.95B | 2.18B | 1.89B | 1.82B |
| Total Liabilities | 1.78B | 1.75B | 1.22B | 1.2B | 1.17B |
| Total Equity | 1.38B | 1.2B | 956.3M | 697.2M | 649.3M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.33B | 2.88B | 2.96B | 3.17B | 1.82B |
| Total Liabilities | 1.24B | 1.44B | 1.34B | 1.78B | 1.17B |
| Total Equity | 1.09B | 1.45B | 1.62B | 1.38B | 649.3M |
| Quarter End | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -34.1M | -184M | -298.4M | -238.4M | -206.3M |
| Investing | -381.3M | -15.1M | 242.6M | 223.7M | 212.3M |
| Financing | 481.2M | -10.5M | -497.4M | -540.4M | -535.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 188M | 536M | 321.1M | -34.1M | -206.3M |
| Investing | -96.9M | -151M | -225M | -381.3M | 212.3M |
| Financing | -35.9M | 69.5M | -141M | 481.2M | -535.7M |
| Market Cap | 262.06M |
| Price to Earnings Ratio | -0.34 |
| Price to Sales Ratio | 0.25 |
| Price to Cash Ratio | 2.35 |
| Price to Book Ratio | 0.4 |
| Dividend Yield | - |
| Shares Outstanding | 52.2M |
| Average Volume (1 week) | 2.36M |
| Average Volume (1 Month) | 11.4M |
| 52 Week Change | -41.15% |
| 52 Week High | 9.96 |
| 52 Week Low | 1.42 |
| Spread (Intraday) | 0.23 (4.38%) |
| Company Name | Emergent Biosolutions Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.emergentbiosolutions.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
